Rahul Banerjee: AURIGA results in IMS 2024 app

Rahul Banerjee shared a post on X:

”AURIGA results in the International Myeloma Society (IMS) 2024 app!

After autologous stem cell transplant (ASCT) in multiple myeloma (MM), 30-month progression-free survival (PFS) was 83% with daratumumab and lenalidomide (Dara-R) versus 66% with lenalidomide (R) alone.

Can’t directly extrapolate to quad induction or MRD- after ASCT, and not powered for PFS…

… but as a previously loud cynic of CD38-R maintenance sans RCT data, I am a changed man.”

Source: Rahul Banerjee/X

Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in hematology and oncology from University of California, San Francisco.   He has authored over 70-peer reviewed publications. His clinical interests include multiple myeloma.